REGQUALITYREVIEW

Evidence for systems that carry regulated work.

Provider capability evidence record

IQVIA SmartSolve and Quality Events And Deviations

What the current official record does—and does not—establish about IQVIA SmartSolve for quality events and deviations.

What the source record establishes

IQVIA SmartSolve combines eQMS and RIM applications on a common platform for quality records, regulatory product information, registrations, submissions, and post-market workflows.

The maintained taxonomy connects that documented market position to Quality Events And Deviations. This page keeps the claim at the level supported by the source: IQVIA SmartSolve presents an offering relevant to this work. It does not silently convert a product description into an observed result, a conformity finding, or a universal recommendation.

Current fit signal: MedTech, IVD, pharmaceutical, or biotechnology organizations evaluating a combined quality and regulatory operating platform with shared master data and workflows.

What quality events and deviations means in this market

Quality Events And Deviations should be evaluated as an operating chain rather than a feature label. The chain begins with a named business condition and governed input, passes through configured logic and accountable review, produces an output or action, handles exceptions, and preserves enough evidence for another person to reconstruct the decision later.

Audit, inspection, and evidence readiness

Risk that the organization cannot retrieve a coherent, accurate, and reviewable evidence chain for an auditor, inspector, certification body, notified body, or internal governance review without manual reconstruction.

Supplier quality and external operations

Risk that suppliers, laboratories, contract manufacturers, service providers, and other external parties are selected, qualified, monitored, changed, and governed without sufficient evidence or connection to product and process risk.

Complaints, post-market quality, and safety handoffs

Risk that complaints, adverse-event indicators, product-quality complaints, vigilance, field actions, recalls, post-market surveillance, and regulatory reporting are delayed or fragmented across quality, safety, medical, regulatory, and commercial systems.

Who owns the decision

A capability can be technically available while operating ownership remains fragmented. The evaluation should name the person accountable for policy or business interpretation, the person responsible for configuration and data, the reviewer with authority to resolve exceptions, the approver of release or action, and the owner of monitoring and retirement.

IQVIA SmartSolve should be asked to distinguish what the product decides, what it recommends, what it merely displays, and what remains an organizational judgment. A generic “human in the loop” statement is inadequate unless the human has time, context, evidence, and authority.

Evidence package to request from IQVIA SmartSolve

  • The exact product and package proposed, with a dated list of native, integrated, partner, service, and customer-owned components.
  • A representative input set, its authoritative source, permitted use, quality checks, and version history.
  • The configured workflow from intake through review, exception, approval, action, retention, and export.
  • A normal result and at least two difficult exceptions, including one caused by missing or contradictory evidence.
  • Role and access definitions for configuration, review, approval, override, monitoring, and administration.
  • An implementation map naming integrations, migrations, customer work, provider work, services, test environments, and release gates.
  • A retained decision record showing source, logic or model version, user action, timestamps, disposition, and downstream effect.
  • A measurement plan with baseline, observation period, population, error threshold, exclusions, and stop condition.

Demonstration script

  1. Which exact IQVIA SmartSolve product, edition, module, service, and geography support quality events and deviations?
  2. What source data, content, rules, and integrations does IQVIA SmartSolve require before the workflow can begin?
  3. Where does human judgment enter, and which person can approve, reject, override, or stop the quality events and deviations workflow?
  4. How does the proposed configuration handle missing data, conflicting evidence, changed rules, and an expired or revoked approval?
  5. What record preserves inputs, transformations, user actions, exceptions, outputs, timestamps, and downstream consequences?
  6. Which parts are native, partner-delivered, service-delivered, or left to the customer?
  7. What can be exported at implementation, audit, renewal, migration, and exit?
  8. Which observation would falsify the current fit hypothesis for IQVIA SmartSolve?
  9. Can a user retrieve the current and historical records for a process, product, site, supplier, or quality issue with their relationships intact?
  10. Which audit-planning, execution, finding, response, commitment, and follow-up records are maintained natively?
  11. How are privileged inspection workspaces or temporary reviewer access created, monitored, and removed?
  12. Can management-review metrics be traced back to underlying records and definitions rather than static presentation slides?

Use the same scenario with every finalist. Let the provider explain differences in architecture, but keep the business condition, required evidence, exception, and expected decision record constant. That makes the evaluation comparable without pretending that unlike products should receive one synthetic score.

Failure modes and boundary conditions

  • a polished normal path that hides missing or contradictory evidence
  • an automation step that exceeds the user's authority
  • a score or generated explanation that cannot be traced to a source and version
  • an exception that disappears into email or an unexportable activity log

Official materials describe an integrated platform and broad module set, but public evidence does not establish the depth of every module, regional coverage, configuration effort, validation deliverables, or availability of individual capabilities in a proposed package.

A buyer should also distinguish absence of public evidence from evidence of absence. If IQVIA SmartSolve has not publicly documented a required detail, the correct status is “not established in this review” until a current, attributable source or direct observation resolves it.

Authority and standards context

FDA 21 CFR Part 11

Electronic quality and regulatory platforms frequently process predicate-rule records. Buyers must evaluate technical controls, procedural controls, intended use, record retention, audit trails, access, signatures, and system lifecycle together rather than accept a generic Part 11 badge.

Interpretation boundary: Part 11 does not approve software products or create a standalone certification. Applicability depends on the predicate record, intended use, and the regulated organization's technical and procedural controls.

This mapping identifies a workflow that may help organize evidence. It does not state that IQVIA SmartSolve conforms to, complies with, or is certified against the authority.

FDA drug CGMP

eQMS products organize records supporting drug CGMP processes, but software boundaries must align with manufacturing, laboratory, ERP, MES, and supplier systems. A feature list alone cannot establish that regulated processes are controlled.

Interpretation boundary: The regulation defines CGMP obligations, not a commercial eQMS specification. Buyers must map their own records and controls to applicable sections and connected systems.

This mapping identifies a workflow that may help organize evidence. It does not state that IQVIA SmartSolve conforms to, complies with, or is certified against the authority.

ISO 13485:2016

The standard is a central organizing reference for medical-device QMS design and is incorporated into the U.S. QMSR. Buyers need systems that can express their own processes and evidence without treating a vendor template as the standard itself.

Interpretation boundary: ISO publishes the standard and does not certify organizations or software. The public ISO page summarizes scope; detailed requirements are in the licensed standard.

This mapping identifies a workflow that may help organize evidence. It does not state that IQVIA SmartSolve conforms to, complies with, or is certified against the authority.

Comparable records to inspect

The following organizations also have current official positioning mapped to quality events and deviations. Inclusion is a research pathway, not a shortlist or claim of equivalence.

  • AmpleLogic — Integrated Quality And Regulatory Platform with documented positioning relevant to Quality Events And Deviations
  • Ennov — Integrated Quality And Regulatory Platform with documented positioning relevant to Quality Events And Deviations
  • Generis CARA — Integrated Quality And Regulatory Platform with documented positioning relevant to Quality Events And Deviations
  • Veeva Systems — Integrated Quality And Regulatory Platform with documented positioning relevant to Quality Events And Deviations
  • Arena QMS — Medical-Device Quality And Product-Lifecycle Platform with documented positioning relevant to Quality Events And Deviations
  • AssurX — Configurable QMS With Life-Sciences Offering with documented positioning relevant to Quality Events And Deviations

Official authority sources

The following primary authority pages support the standards context used in this record. They define an evaluation boundary; they do not endorse IQVIA SmartSolve or establish product conformity.

FDA 21 CFR Part 11

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

FDA drug CGMP

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

ISO 13485:2016

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

Conditional conclusion

IQVIA SmartSolve belongs in deeper evaluation for quality events and deviations when its documented integrated quality and regulatory platform operating model matches the buyer's real workflow, the proposed package contains the required components, and a representative test produces reviewable evidence through normal and exception paths. The conclusion should be reversed or narrowed when the product boundary, source data, authority mapping, integration burden, human decision rights, exportability, or measured result does not meet the stated approval conditions.

Official provider source: IQVIA SmartSolve.

Record date: 2026-07-19T14:57:00.000Z. The date records the maintained source review, not an independent product test.

Editorial boundary: RegQuality Review is not a regulator, certification body, law firm, or validation authority. Its records support research and decision review; they do not establish compliance for an organization, system, release, configuration, or intended use.

Methodology · Submit a source-backed correction